Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
|Articles|March 2, 2011
- January 2011
- Volume 5
- Issue 1
Men With Prostate Cancer Should Exercise
Author(s)Marissa Murtaugh
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week
Advertisement
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week. Men who perform vigorous exercise for >3 hours each week lower their overall mortality risk by 49%, suggests a study published in the Journal of Clinical Oncology. In addition, they reduce their risk of death from prostate cancer by 61% compared with men who exercise <1 hour each week. Outcomes are best for men who exercised routinely before diagnosis and continue to do so.
Articles in this issue
over 15 years ago
Cancer in the Workplaceover 15 years ago
Developing Optimal Patient Medication InformationAdvertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
China's NMPA Approves Pirtobrutinib Across CLL
5